Cargando…
Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial
OBJECTIVE: To evaluate the efficacy, tolerability, and safety of once-daily 1200 mg and 2400 mg SPN-804 (Oxtellar XR™, Supernus Pharmaceuticals), an extended-release tablet formulation of oxcarbazepine (OXC), added to 1-3 concomitant antiepileptic drugs (AEDs) in adults with refractory partial-onset...
Autores principales: | French, JA, Baroldi, P, Brittain, ST, Johnson, JK |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033571/ https://www.ncbi.nlm.nih.gov/pubmed/24359313 http://dx.doi.org/10.1111/ane.12207 |
Ejemplares similares
-
Long‐term efficacy and safety of adjunctive extended‐release oxcarbazepine (Oxtellar XR(®)) in adults with partial‐onset seizures
por: Chung, S. S., et al.
Publicado: (2015) -
Predicted Efficacy of Once-Daily Extended-Release Oxcarbazepine (Oxtellar XR(®)) Monotherapy in Adults and Children with Partial-Onset Seizures: Exposure-Response Modeling and Simulation
por: Faison, Shamia, et al.
Publicado: (2020) -
Clinical utility of adjunctive retigabine in partial onset seizures in adults
por: Rejdak, Konrad, et al.
Publicado: (2012) -
Efficacy of Retigabine in Adjunctive Treatment of Partial Onset Seizures in Adults
por: Splinter, Michele Y.
Publicado: (2013) -
Levetiracetam Extended Release as Adjuvant Therapy for the Control of Partial-onset Seizures
por: Sonmezturk, Hasan H., et al.
Publicado: (2011)